Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
| Website | https://indapta.com/ |
| Employees | 14 (5 on RocketReach) |
| Founded | 2017 |
| Industry | Biotechnology, Drug Discovery |
| Keywords | Cell Therapy, Oncology Therapeutics, Cancer Treatment, Immuno-Oncology, Cancer Immunotherapy, Monoclonal Antibodies, Immunotherapy Treatment, Targeted Therapy, Novel Therapeutics, Adc, Cancer Research, Biopharmaceutical, Pharmaceutical Research, Drug Development, Clinical Stage |
| Competitors | Moderna Therapeutics, CureVac, Novavax, GSK, Pfizer, AstraZeneca, Sanofi, INOVIO Pharmaceuticals, Inc., Vaxart, Inc., Replimune +42 more (view full list) |
Looking for a particular Indapta Therapeutics employee's phone or email?
Indapta Therapeutics Questions
Mark Frohlich is the CEO of Indapta Therapeutics.
5 people are employed at Indapta Therapeutics.
Top Indapta Therapeutics Employees
-
Mark Frohlich
Chief Executive Officer at Indapta Therapeutics
Kirkland, WA, US25+ -
Guy Dipierro
Chief Operating Officer and Founder at Indapta Therapeutics
San Francisco, CA, US25+ -
Stefanie Mandl-Cashman
Acting Chief Scientific Officer at Indapta Therapeutics
San Francisco, CA, US1 -
12
Related Companies
G2Crowd Trusted
300K+
Plugin Users
